Mardi Dier to lead financial operations

  • Madrigal Pharmaceuticals hires Mardi Dier as new CFO
  • Dier will replace Alex Howarth
  • Howarth will remain as a senior adviser until March 31
  • Dier’s annual base salary is $550,000
  • Howarth entitled to benefits related to termination without cause

Madrigal Pharmaceuticals has announced the appointment of Mardi Dier as its new Chief Financial Officer. Dier will be replacing Alex Howarth, who has served as the company’s CFO since May 2021. Howarth will continue to support the transition as a senior adviser until March 31. Dier brings extensive experience to the role, having previously served as CFO of Acelyrin. Her annual base salary will be $550,000, with an annual bonus target of 45% of her base pay. In the event of termination without cause, Howarth will receive benefits including payment of his base salary for 12 months and the target bonus for the current year.

Factuality Level: 8
Factuality Justification: The article provides factual information about the change in leadership at Madrigal Pharmaceuticals, including the names of the individuals involved, their positions, and key details such as start dates, salaries, and bonuses. The article does not contain any irrelevant information, misleading details, sensationalism, redundancy, or opinion masquerading as fact.
Noise Level: 2
Noise Justification: The article provides relevant information about the change in leadership at Madrigal Pharmaceuticals, including details about the new CFO and the transition plan. It stays on topic and does not contain exaggerated reporting or irrelevant information. However, it lacks in-depth analysis, antifragility insights, or accountability of powerful people.
Financial Relevance: Yes
Financial Markets Impacted: Madrigal Pharmaceuticals
Presence Of Extreme Event: No
Nature Of Extreme Event: No
Impact Rating Of The Extreme Event: No
Rating Justification: This news article pertains to the financial topic of executive changes within Madrigal Pharmaceuticals. It does not describe any extreme events or their impacts.
Public Companies: Madrigal Pharmaceuticals (N/A)
Private Companies: Acelyrin
Key People: Mardi Dier (Chief Financial Officer), Alex Howarth (Senior Adviser)

Reported publicly: www.marketwatch.com